XNCR Logo

Xencor, Inc. (XNCR) 

NASDAQ
Market Cap
$1.58B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
327 of 776
Rank in Industry
196 of 433

Largest Insider Buys in Sector

XNCR Stock Price History Chart

XNCR Stock Performance

About Xencor, Inc.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted …

Insider Activity of Xencor, Inc.

Over the last 12 months, insiders at Xencor, Inc. have bought $1,013 and sold $4.17M worth of Xencor, Inc. stock.

On average, over the past 5 years, insiders at Xencor, Inc. have bought $1,013 and sold $11.46M worth of stock each year.

Highest buying activity among insiders over the last 12 months: GORMAN KEVIN CHARLES (director) — $2,027.

The last purchase of 53 shares for transaction amount of $1,013 was made by GORMAN KEVIN CHARLES (director) on 2024‑02‑13.

List of Insider Buy and Sell Transactions, Xencor, Inc.

2024-09-27Saledirector
2,503
0.0036%
$20.68$51,762+3.80%
2024-09-27Saledirector
1,853
0.0027%
$20.68$38,320+3.80%
2024-09-27Saledirector
2,503
0.0036%
$20.68$51,762+3.80%
2024-09-27Saledirector
2,503
0.0036%
$20.68$51,762+3.80%
2024-09-27Saledirector
2,503
0.0036%
$20.68$51,762+3.80%
2024-09-27Saledirector
2,654
0.0038%
$20.68$54,885+3.80%
2024-07-09SaleSR. VICE PRESIDENT & CSO
36,329
0.0555%
$18.32$665,5110.00%
2024-05-02SaleEVP, Chief Development Officer
4,745
0.0077%
$23.58$111,872-11.82%
2024-03-11SalePRESIDENT & CEO
2,741
0.0046%
$23.50$64,418-9.22%
2024-03-11SaleSR. VICE PRESIDENT & CSO
1,280
0.0021%
$23.50$30,082-9.22%
2024-03-11SaleSR. VICE PRESIDENT & CFO
849
0.0014%
$23.50$19,953-9.22%
2024-03-11SaleSVP, GENERAL COUNSEL
850
0.0014%
$23.50$19,977-9.22%
2024-03-06Saledirector
14,000
0.0222%
$23.18$324,453-11.67%
2024-03-05SalePRESIDENT & CEO
12,528
0.0209%
$23.43$293,519-7.86%
2024-03-05SaleSR. VICE PRESIDENT & CSO
6,629
0.011%
$23.43$155,311-7.86%
2024-03-05SaleSR. VICE PRESIDENT & CFO
4,474
0.0075%
$23.43$104,821-7.86%
2024-03-05SaleSVP, GENERAL COUNSEL
3,892
0.0065%
$23.43$91,186-7.86%
2024-02-13SaleSR. VICE PRESIDENT & CSO
54,108
0.084%
$19.38$1.05M+11.04%
2024-02-13Purchasedirector
53
<0.0001%
$19.12$1,013+11.04%
2023-12-29SalePRESIDENT & CEO
45,000
0.073%
$20.93$941,670-0.78%

Insider Historical Profitability

42.31%
GORMAN KEVIN CHARLESdirector
8392
0.012%
$22.5411
STAFFORD JOHN S JR10 percent owner
2000443
2.8608%
$22.5410+31.06%
STAFFORD JOHN S III10 percent owner
606005
0.8666%
$22.543342+42.66%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$244.64M17.9311.05M-2.37%-$5.95M0.01
PRIMECAP Management Co$201.18M14.749.09M+2.12%+$4.18M0.15
The Vanguard Group$155.15M11.377.01M+3.6%+$5.4M<0.01
Ecor1 Capital Llc$117.96M8.645.33M+0.91%+$1.06M0.83
State Street$93.73M6.874.24M+27.31%+$20.11M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.